OTC · ISCO
International Stem Cell Corporation
$0.14-$0.04 (-22.22%)
International Stem Cell Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.07% below the high.
Loading market information…
OTC · HALB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Halberd Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Halberd Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.14-$0.04 (-22.22%)
International Stem Cell Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.07% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$0.01-$0.00 (-7.69%)
Evofem Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
$3.29$0.00 (0.0%)
Helix BioMedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.38% below the high.
$0.00$0.00 (0.0%)
Neutra Corp.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.05$0.00 (0.0%)
Orgenesis Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.87% below the high.
$0.01$0.00 (0.0%)
LiveCare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.67% below the high.
$0.00$0.00 (0.0%)
Marizyme, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.3% below the high.
